Glenmark Starts Revamilast Phase IIb Trials

Indian drugmaker Glenmark Pharmaceuticals has started Phase IIb trials to evaluate Revamilast as a treatment for inflammatory disorders like rheumatoid arthritis and asthma.
PBR